Phase II Study of ASP7373 Evaluation of Immunogenicity and Safety of ASP7373 in Healthy Adults.

Trial Profile

Phase II Study of ASP7373 Evaluation of Immunogenicity and Safety of ASP7373 in Healthy Adults.

Completed
Phase of Trial: Phase II

Latest Information Update: 03 Oct 2017

At a glance

  • Drugs Influenza A virus vaccine-H5N1 (Primary)
  • Indications Influenza A virus H5N1 subtype
  • Focus Adverse reactions
  • Most Recent Events

    • 13 Mar 2012 The vaccine showed immunogenicity and favourable safety profile, according to Astellas Pharma and UMN Pharma media release
    • 20 Jan 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 11 Nov 2011 Astellas confirms in a company media release that vaccine administration has been successfully completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top